Literature DB >> 18432938

Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

David C Montefiori1.   

Abstract

Neutralizing antibody assays are powerful tools for assessing humoral immunity in AIDS virus infection and vaccine development. Although many different assays have been described, all are based on the same principle, measuring reductions in virus infectivity. This unit describes two assays utilizing a genetically engineered cell lines that are susceptible to infection by most strains of HIV-1, SIV, and SHIV. One assay is designed for optimal performance with uncloned viruses produced in either PBMC or CD4+ T cell lines. A second assay is designed for single-cycle infection with molecularly cloned pseudoviruses produced by transfection in 293T cells. Both assays are performed in a 96-well format and use tat-responsive luciferase reporter gene expression as readout.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 18432938     DOI: 10.1002/0471142735.im1211s64

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  308 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Authors:  Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini
Journal:  J Immunol       Date:  2014-11-14       Impact factor: 5.422

3.  Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

Authors:  José das Neves; Johan Michiels; Kevin K Ariën; Guido Vanham; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2011-11-10       Impact factor: 4.200

4.  Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Authors:  Mattia Bonsignori; David C Montefiori; Xueling Wu; Xi Chen; Kwan-Ki Hwang; Chun-Yen Tsao; Daniel M Kozink; Robert J Parks; Georgia D Tomaras; John A Crump; Saidi H Kapiga; Noel E Sam; Peter D Kwong; Thomas B Kepler; Hua-Xin Liao; John R Mascola; Barton F Haynes
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

Authors:  Christopher A Todd; Kelli M Greene; Xuesong Yu; Daniel A Ozaki; Hongmei Gao; Yunda Huang; Maggie Wang; Gary Li; Ronald Brown; Blake Wood; M Patricia D'Souza; Peter Gilbert; David C Montefiori; Marcella Sarzotti-Kelsoe
Journal:  J Immunol Methods       Date:  2011-09-22       Impact factor: 2.303

6.  Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.

Authors:  Tara G Edmonds; Haitao Ding; Xing Yuan; Qing Wei; Kendra S Smith; Joan A Conway; Lindsay Wieczorek; Bruce Brown; Victoria Polonis; John T West; David C Montefiori; John C Kappes; Christina Ochsenbauer
Journal:  Virology       Date:  2010-09-21       Impact factor: 3.616

7.  Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus.

Authors:  Jennifer D Watkins; Juan Diaz-Rodriguez; Nagadenahalli B Siddappa; Davide Corti; Ruth M Ruprecht
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

8.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Authors:  Charlotta Nilsson; Karina Godoy-Ramirez; Bo Hejdeman; Andreas Bråve; Lindvi Gudmundsdotter; David Hallengärd; Jeffrey R Currier; Lindsay Wieczorek; Klara Hasselrot; Patricia L Earl; Victoria R Polonis; Mary A Marovich; Merlin L Robb; Eric Sandström; Britta Wahren; Gunnel Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-15       Impact factor: 2.205

10.  Binding Site Geometry and Subdomain Valency Control Effects of Neutralizing Lectins on HIV-1 Viral Particles.

Authors:  Sabrina Lusvarghi; Katheryn Lohith; Jeanne Morin-Leisk; Rodolfo Ghirlando; Jenny E Hinshaw; Carole A Bewley
Journal:  ACS Infect Dis       Date:  2016-10-03       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.